Alkylating agents
Chemoradiotherapy + Stem Cell Transplant for Blood Cancers
This trial is giving chemotherapy drugs and HT before a donor stem cell transplant to see if it helps stop the growth of cancer cells and also helps stop the patient's immune system from rejecting the donor's stem cells.
Dietary Supplement
Vitamin C for Myelodysplastic Syndrome
This trial tests if taking vitamin C daily can help patients with certain low-risk blood cancers. These patients often have low vitamin C levels, which might affect their DNA. By boosting vitamin C, the study aims to see if it can improve DNA health and slow cancer progression. Vitamin C has been studied for its potential effects on cancer prevention and treatment, with some evidence suggesting it may improve quality of life and defense reactions in cancer patients.
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor
JNJ-64619178 for Cancer
This trial is testing a new cancer drug to see what doses are tolerated by patients with different types of cancer, including lymphoma and solid tumors. The goal is to also find out what doses of the drug might be effective in treating these cancers.
Popular Filters
Trials for MDS Patients
Alkylating agents
IM-TMI + Chemotherapy for AML and MDS
This trial is testing whether adding a new kind of radiation to the standard myeloablative fludarabine/ i.v. targeted busulfan conditioning improves outcomes for patients receiving allogeneic hematopoietic stem cell transplant (HSCT).
Alkylating agents
Cord Blood Transplant for Blood Diseases
This trial uses stem cells from a baby's umbilical cord to treat patients who need new healthy stem cells. Patients first get strong medicine to clear out unhealthy cells, then receive the new stem cells, and take medications to prevent complications. Umbilical cord blood has been used in the treatment of various diseases, including leukemias, lymphomas, and immune system disorders.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
Trials for Myelomonocytic Leukemia Patients
Alkylating agents
IM-TMI + Chemotherapy for AML and MDS
This trial is testing whether adding a new kind of radiation to the standard myeloablative fludarabine/ i.v. targeted busulfan conditioning improves outcomes for patients receiving allogeneic hematopoietic stem cell transplant (HSCT).
Alkylating agents
Cord Blood Transplant for Blood Diseases
This trial uses stem cells from a baby's umbilical cord to treat patients who need new healthy stem cells. Patients first get strong medicine to clear out unhealthy cells, then receive the new stem cells, and take medications to prevent complications. Umbilical cord blood has been used in the treatment of various diseases, including leukemias, lymphomas, and immune system disorders.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
Trials for HLA-A Positive Patients
CAR T-cell Therapy
Gene Modified T-cells for Blood Disorders
This trial will look at whether T cells from a family member can help a patient's immune system recover after a stem cell transplant, with the added safety measure of a self-destruct switch.
Alkylating agents
Bone Marrow Transplant for Blood Cancers
This trial tests a stem cell transplant for patients who need a transplant but don't have a perfect match. The process uses a less intense preparation method and aims to see if patients remain disease-free over time.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Procedure
Experimental Drug for Leukemia Post-Stem Cell Transplant
This trial is testing two different doses of an experimental drug to see if it is safe and effective in treating patients with leukemia who have received a stem cell transplant from a related donor.
Phase 3 Trials
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Anti-metabolites
Cedazuridine + Azacitidine for Leukemia
This trial tests a new pill form of two drugs, cedazuridine and azacitidine, for patients needing azacitidine treatment. The goal is to see if the pill is as effective as the injection. Cedazuridine helps azacitidine work better by preventing its breakdown, and azacitidine stops cancer cells from growing.
Cancer Treatment
Epoetin Alfa vs Luspatercept for Myelodysplastic Syndrome
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
Trials With No Placebo
Alkylating agents
IM-TMI + Chemotherapy for AML and MDS
This trial is testing whether adding a new kind of radiation to the standard myeloablative fludarabine/ i.v. targeted busulfan conditioning improves outcomes for patients receiving allogeneic hematopoietic stem cell transplant (HSCT).
Alkylating agents
Cord Blood Transplant for Blood Diseases
This trial uses stem cells from a baby's umbilical cord to treat patients who need new healthy stem cells. Patients first get strong medicine to clear out unhealthy cells, then receive the new stem cells, and take medications to prevent complications. Umbilical cord blood has been used in the treatment of various diseases, including leukemias, lymphomas, and immune system disorders.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
View More Related Trials
Frequently Asked Questions
Introduction to myelodysplastic syndrome
What are the top hospitals conducting myelodysplastic syndrome research?
When it comes to advancing the treatment options for myelodysplastic syndrome, several top hospitals across the United States are leading the way. In Boston, renowned institutions like Dana Farber Cancer Institute and Massachusetts General Hospital have dedicated considerable efforts to combat this condition. Dana Farber Cancer Institute currently has 13 active clinical trials focusing on myelodysplastic syndrome, building upon their extensive repertoire of 42 past trials since their first recorded trial in 2001. Similarly, Massachusetts General Hospital is making notable progress with seven ongoing trials and an impressive history of 47 previous studies dating back to their earliest involvement in researching this disorder in 1984.
Meanwhile, University of Miami in sunny Miami and Washington University School of Medicine in Saint Louis are also integral players when it comes to pushing boundaries against myelodysplastic syndrome. The former institution is conducting seven active clinical trials while having completed a total of 16 successful investigations since embarking on this journey in 2006. On the other hand, Washington University School of Medicine boasts six ongoing clinical tests and a commendable track record of contributing towards understanding myelodysplastic syndrome through their involvement in around41 earlier trials commencing from as early as2003.
Notably adding itself into this prestigious group is Fred Hutchinson Cancer Research Center situated amidst Seattle's vibrant atmosphere; they too conduct research regarding MDS (MyeloDySPlastic Syndrome) via actively performing six current experimental divisions along with being recognized globally for having taken partin eighty-five previous experiments that commenced from1991 onwards.
These esteemed institutions not only provide hope for individuals affected by myelodysplastic syndrome but also symbolize the tireless pursuit towards unraveling mysteries surrounding this condition nationwide. By collaborating together and pioneering innovative clinical trials, these hospitals bring us one step closer each day towards finding effective treatments and improving lives impacted by MDS
Which are the best cities for myelodysplastic syndrome clinical trials?
When it comes to myelodysplastic syndrome clinical trials, several cities stand out as top contenders for research and development. Boston, Massachusetts leads the pack with 36 active trials focusing on treatments like H3B-8800 (RVT-2001) Dose Escalation, Venetoclax, and Inqovi. Following closely behind is Houston, Texas with 27 ongoing studies exploring therapies such as BGB-11417 and CC-95251. New york City also plays a significant role in advancing treatment options with 20 active trials investigating interventions like Bone Marrow Hematopoietic Stem Cell Transplantation and Oral Azacitidine. Other notable cities include Miami, Florida with 19 active trials and Chicago, Illinois with 17 active trials. These cities offer individuals affected by myelodysplastic syndrome access to cutting-edge clinical trials that have the potential to transform care outcomes significantly.
Which are the top treatments for myelodysplastic syndrome being explored in clinical trials?
In the world of myelodysplastic syndrome research, several promising treatments are making waves in ongoing clinical trials. CPX-351 stands out with its involvement in two active trials and a total of 11 past trials dedicated to this condition since its introduction in 2009. Another contender is luspatercept, currently being explored in two active studies and having been listed for myelodysplastic syndrome research since 2016 with a cumulative count of 15 trials. Also on the radar is MBG453, showing potential through participation in two ongoing trials and seven historical ones since its listing in 2017. Lastly, atorvastatin enters the fray with two current investigations and three prior myelodysplastic syndrome clinical trials after joining the scene just recently in 2018. As researchers delve deeper into these avenues of exploration, new hope emerges for individuals battling myelodysplastic syndrome worldwide.
What are the most recent clinical trials for myelodysplastic syndrome?
Exciting progress is being made in the realm of myelodysplastic syndrome, with recent clinical trials offering hope and potential advancements for patients. Among these trials is the investigation of Sitagliptin + Bortezomib + Cyclophosphamide as a treatment option, showing promise in Phase 1 and Phase 2 studies. Additionally, a Phase 2 trial explores CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplantation utilizing the Busulfan/Melphalan/Fludarabine Regimen to address this condition. Itacitinib has also emerged as an area of interest in a Phase 1 study for myelodysplastic syndrome. Another trial focuses on Cy/Flu/TBI paired with Post-transplant CY therapy. Lastly, Dose Escalation Cohorts are being analyzed across Phases 1 and 2 to assess their efficacy against myelodysplastic syndrome. These endeavors signify significant strides towards improved outcomes for individuals affected by this disorder.
What myelodysplastic syndrome clinical trials were recently completed?
In recent years, a plethora of clinical trials have been conducted to advance the understanding and treatment options for myelodysplastic syndrome (MDS). Noteworthy completed trials include the investigation of Lemzoparlimab by AbbVie in June 2021, sabatolimab by Novartis Pharmaceuticals in May 2021, Azacitidine by Pfizer in May 2021. Other notable studies encompassed Salsalate by Rutgers University in October 2020, Recombinant Interleukin-7 by M.D. Anderson Cancer Center in September 2020, PRT1419 by Prelude Therapeutics also in September 2020, and CB-5339 by Cleave Therapeutics Inc. in June 2020. These comprehensive efforts collectively contribute towards advancing therapeutic strategies for individuals affected by MDS - a condition characterized by impaired blood cell production primarily affecting older adults.